Zycortal 25mg/mL - 4mL Vial
This is a prescription medicine. Please ensure that you have read the "How to Order" page before ordering this item.
We apologise that we are unable to display a photograph of the packaging or provide you with more information regarding this prescription medicine. Australian legislation prohibits the advertisement of prescription drugs to consumers.
All of our products are APVMA or TGA approved and identical to those used by your veterinarian. Please call or email us if you have any queries about any of the products on our site.
|Indication||For use as replacement therapy for mineralocorticoid deficit in dogs with primary hypoadrenocorticism (Addison disease).|
|Contraindications||Administration to immature growing dogs (small and medium breeds up to 8 months of age, large breeds up to 12 months of age, giant breeds up to 18 months of age) and in cats less than 12 months of age. Marbofloxacin and other quinolones have been shown to cause arthropathy in immature animals of most species tested, the dog being particularly sensitive to this side effect.Administration to dogs and cats known to be hypersensitive to quinolones.|
|Actions||Deoxycortone is a corticosteroid with primarily mineralocorticoid activity, similar to the natural mineralocorticoid hormone aldosterone. In the kidney, deoxycortone induces electrolyte transport through stimulation of sodium potassium adenosine triphosphatase and activation of the sodium-hydrogen ion exchanger, which leads to sodium and chloride ion influx into the cell, and hydrogen and potassium excretion. Sodium, chloride and bicarbonate retention creates an osmotic gradient that promotes water absorption from the renal tubules and increases extracellular fluid volume. Net effects include blood volume expansion, with increased venous return to the heart, and increased cardiac output.Clinical signs in dogs with hypoadrenocorticism may include hypovolaemia, dehydration, prerenal azotaemia and inadequate tissue perfusion. Use of Zycortal addresses the mineralocorticoid deficit that underlies these clinical signs but requires a functional kidney.|
|Precautions||Use with caution in any dog presenting with severe hypovolaemia, dehydration, prerenal azotaemia and inadequate tissue perfusion (Addisonian crisis) and rehydrate such dogs with intravenous fluid (saline) therapy before starting treatment with Zycortal. Caution is needed if concurrently using potassium depleting diuretics which may cause hypokalaemia.|
|Dosage and Administration||Gently shake the vial to resuspend the product before use.Zycortal replaces the mineralocorticoid hormones only. Dogs with combined glucocorticoid and mineralocorticoid deficiency must also be treated with a glucocorticoid at a physiological replacement dose. Dose. The initial dosage is 2.2 mg/kg bodyweight, administered by subcutaneous injection, and repeated in 25 days. This dose and/or treatment interval may need to be varied based on individual clinical response. The dosage of Zycortal and the concurrently administered glucocorticoid replacement therapy must be tailored to the individual animal. Eight to 10 days after the first dose of Zycortal, evaluate the serum sodium:potassium ratio. At approximately 25 days after the first dose of Zycortal, re-evaluate the sodium:potassium ratio and give second and subseqent doses as detailed in literature with product. General directions. In anticipation of stressful situations, increase the dosage of the replacement glucocorticoid. In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.|
|Storage||Store below 25°C (air conditioning). Keep the vial in the outer carton to protect from light. Do not freeze. Use contents within 120 days of first broaching vial.|
|Manufacturer||Dermcare-Vet Pty Ltd|